Last reviewed: June 16, 2026
Last updated: June 16, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1 receptor agonists have transformed weight management for over 9 million Americans, yet these powerful medications are not appropriate for everyone. The U.S. FDA has identified specific groups who face unacceptable health risks from GLP-1 therapy, and PlexusDx screens all patients to ensure safe eligibility before starting treatment.
Absolute Contraindications: When GLP-1 Therapy Is Off Limits
Certain medical histories completely disqualify patients from GLP-1 use. Anyone with a personal or family history of medullary thyroid carcinoma (MTC) must avoid these medications, as animal studies show GLP-1 agonists increase C-cell proliferation in thyroid tissue. Similarly, patients diagnosed with multiple endocrine neoplasia syndrome type 2 (MEN2) face dangerous risks because the genetic condition predisposes the thyroid to malignant growth when exposed to GLP-1 stimulation.
Pregnancy represents another absolute barrier to GLP-1 therapy. No human safety data exists for semaglutide, tirzepatide, or other GLP-1 compounds during pregnancy, and animal models show fetal skeletal abnormalities at high doses. Women of childbearing age using these medications must maintain reliable contraception and stop treatment immediately if pregnancy is planned or confirmed. The compounded semaglutide injection (starting at $149/mo) and all other PlexusDx GLP-1 formulations carry pregnancy warnings that patients must understand before enrollment.
Pancreatitis History and Gallbladder Disease Risks
Patients with a history of acute or chronic pancreatitis should generally avoid GLP-1 therapy without specialized medical evaluation. While the absolute risk remains debated in medical literature, GLP-1 agonists slow gastric emptying and increase bile viscosity—mechanisms that theoretically increase pancreatitis recurrence. Any patient with prior pancreatic inflammation must discuss GLP-1 eligibility with their gastroenterologist and primary care physician before initiating treatment through PlexusDx.
Gallstone disease and rapid weight loss create a compounding risk profile. GLP-1 medications accelerate fat loss, which can precipitate gallstone formation in susceptible individuals. Patients with known gallstones, a history of cholecystitis, or those who have undergone gallbladder removal should inform PlexusDx providers before starting any GLP-1 regimen, as dose escalation may require closer monitoring or alternative therapies.
Diabetic Retinopathy and Vision-Threatening Eye Disease
Patients with established diabetic retinopathy—particularly those with severe non-proliferative or proliferative disease—face potential vision complications from GLP-1 induced rapid glucose lowering. The SUSTAIN-6 trial documented worsening of existing retinopathy in some semaglutide users, likely because sudden improvements in blood sugar outpace the eye's ability to compensate. Those with pre-existing diabetic eye disease require ophthalmology clearance and closer glucose monitoring if GLP-1 therapy proceeds.
Similarly, patients with history of retinal detachment, untreated age-related macular degeneration, or other serious retinal conditions should approach GLP-1 use cautiously. The rapid metabolic shifts these medications produce can stress compromised retinal tissue. PlexusDx screens for these ophthalmologic contraindications during the initial medical history review to prevent serious vision loss.
Thyroid Disease, Kidney Disease, and Medication Interactions
Patients with a history of thyroid cancer other than MTC still require careful risk assessment before GLP-1 initiation. While papillary and follicular thyroid cancers do not carry the same mechanistic risk as medullary disease, any previous thyroid malignancy warrants discussion with an endocrinologist. Additionally, those taking thyroid replacement medication (levothyroxine) must monitor absorption, as GLP-1 induced slower gastric motility can reduce drug bioavailability and necessitate dose timing adjustments.
Severe kidney disease (eGFR below 30 mL/min/1.73m²) represents a relative contraindication requiring specialist input. GLP-1 agonists concentrate in renal tissue, and severely diminished kidney function may increase systemic exposure and adverse effects. Patients on dialysis or with advanced chronic kidney disease should obtain nephrology approval before enrolling in PlexusDx therapy. Additionally, anyone taking certain diabetes medications (sulfonylureas, insulin) faces increased hypoglycemia risk when combining these drugs with GLP-1 agents, necessitating dose reductions supervised by qualified physicians.
Genetic Factors and Personalized Safety Assessment
Individual genetic variation affects how bodies respond to GLP-1 therapy, influencing both efficacy and safety profiles. PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after first month) which analyzes key variants in the GLP1R gene (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) among 14 mapped pathways covering 49 peptides. Patients with certain genetic predispositions may face elevated risks for specific side effects or contraindications previously unrecognized in standard screening.
For example, specific GLP1R genetic variants correlate with heightened nausea susceptibility and increased risk of severe gastrointestinal adverse events. Understanding these peptide-pathway predispositions allows PlexusDx to personalize treatment selection—choosing oral semaglutide over injections, adjusting microdose protocols, or recommending alternative approaches entirely. Genetic insights empower safer, more tolerable weight loss journeys tailored to individual biology rather than one-size-fits-all protocols.
How PlexusDx Ensures Safe Patient Selection
Before any patient receives compounded semaglutide injection or any other GLP-1 medication from PlexusDx, a comprehensive medical screening identifies contraindications and risk factors. PlexusDx partners exclusively with licensed 503A compounding pharmacies—never 503B facilities—ensuring pharmaceutical-grade quality and safety standards. The onboarding process includes detailed questionnaires about personal medical history, family cancer history, pregnancy status, kidney function, thyroid disease, and concurrent medications that interact dangerously with GLP-1 therapy.
PlexusDx physicians review each patient's complete profile and may order additional laboratory tests or imaging to clarify risk before treatment initiation. This gate-keeping process protects vulnerable populations and ensures that only candidates with favorable risk-benefit ratios proceed to therapy. Patients can start semaglutide injection at $149/mo with confidence that their individual safety has been thoroughly evaluated by licensed medical professionals, not automated algorithms.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
I have a family history of thyroid cancer. Can I safely use GLP-1 medications?
If your family history includes medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2), GLP-1 therapy is contraindicated because these medications stimulate thyroid C-cells, raising cancer risk. Other thyroid cancer types allow GLP-1 use with endocrinology clearance, but you must disclose complete family history during PlexusDx screening.
I have type 2 diabetes and take insulin. Can I start semaglutide injection?
GLP-1 agonists like semaglutide lower blood sugar through multiple mechanisms, creating significant hypoglycemia risk when combined with insulin. PlexusDx providers can manage this combination, but insulin doses typically require reduction before semaglutide therapy begins, necessitating close medical supervision and frequent glucose monitoring.
Does PlexusDx screen for all contraindications before treatment starts?
Yes. PlexusDx conducts thorough medical history review, asks about pancreatitis, gallbladder disease, thyroid cancer, kidney function, and retinal disease before dispensing any compounded medication from licensed 503A pharmacies. Patients can start semaglutide injection at $149/mo only after physician approval, ensuring personalized safety assessment.
I'm planning to become pregnant. Should I stop GLP-1 therapy now?
Yes. No human safety data supports GLP-1 use during pregnancy, and animal studies show fetal skeletal abnormalities at high doses. Stop GLP-1 therapy before conception and maintain reliable contraception while using any PlexusDx medication. Discuss timing with your PlexusDx provider and OB/GYN.
How does the Precision Peptide Genetic Test identify contraindication risks?
PlexusDx's $99 genetic test analyzes GLP1R, GIPR, FTO, and MC4R variants across 14 mapped pathways, revealing individual predispositions to severe nausea, GI side effects, and metabolic responses. Certain genetic profiles may indicate heightened safety risks or suggest alternative PlexusDx formulations (oral vs. injection, dual-compound options, or microdose protocols) that better suit your biology.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can You Take GLP-1 While Nursing? Understanding the Safety of Semaglutide and Tirzepatide for Breastfeeding Mothers
Who Should Not Take GLP-1 Medications: A Comprehensive Guide